A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB. Participants will: * Apply the study patches every day for 12 weeks and wear each patch for a full day * Visit the clinic once every 2 to 4 weeks for checkups and tests * Keep diaries about their bladder symptoms and the times they change their study patches
Epistemonikos ID: 2aa1f74c6b761790a9326cbcdc011dc43e8be0b3
First added on: Oct 31, 2026